Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222105
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPasnoor, Mamatha-
dc.contributor.authorAnderson Smits, Colin-
dc.contributor.authorLevine, Todd-
dc.contributor.authorBril, Vera-
dc.contributor.authorMarcos Solano, Juan-
dc.contributor.authorRejdak, Konrad-
dc.contributor.authorGamez, Josep-
dc.contributor.authorChroni, Elisabeth-
dc.contributor.authorCasasnovas, Carlos-
dc.contributor.authorMarchioni, Enrico-
dc.contributor.authorSiciliano, Gabriele-
dc.contributor.authorCocito, Dario-
dc.contributor.authorSivakumar, K.-
dc.contributor.authorRivero, Alberto-
dc.contributor.authorDuff, Kim-
dc.contributor.authorGreco, Erin-
dc.contributor.authorCorbo, Massimo-
dc.contributor.authorHasan, Shabbir-
dc.contributor.authorDori, Amir-
dc.contributor.authorSchmidt, Jens-
dc.contributor.authorWood, Jamie-
dc.contributor.authorLi, Zhaoyang-
dc.contributor.authorAy, Hakan-
dc.date.accessioned2025-07-08T10:44:16Z-
dc.date.available2025-07-08T10:44:16Z-
dc.date.issued2025-04-01-
dc.identifier.issn1468-1331-
dc.identifier.urihttps://hdl.handle.net/2445/222105-
dc.description.abstractBackground ADVANCE-CIDP IVIG evaluated the efficacy and safety of immune globulin infusion (human) 10% solution (IVIG 10%; GAMMAGARD LIQUID, also known as Kiovig) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as a rescue treatment for patients relapsing during the ADVANCE-CIDP 1 trial.MethodsOpen-label ADVANCE-CIDP IVIG included adult patients with confirmed CIDP relapse (>= 1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment [INCAT] disability scores from pre-treatment baseline) during ADVANCE-CIDP 1, which assessed the efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10%. Patients received an induction IVIG 10% dose (2 g/kg) followed by maintenance infusions at the same monthly equivalent dose of pre-randomization IVIG, 3-weekly for 6 months. The primary outcome was the responder rate (>= 1-point decrease in adjusted INCAT scores at treatment cessation vs. pre-IVIG 10% baseline, in patients receiving placebo in ADVANCE-CIDP 1). Other outcomes included the responder rate across all patients relapsing on fSCIG 10% or placebo in ADVANCE-CIDP 1, time to functional improvement (>= 1-point decrease in adjusted INCAT score), and change in adjusted INCAT scores and Rasch-built Overall Disability Scale (R-ODS) centile scores from pre-IVIG 10% baseline.ResultsOverall, 20 patients received IVIG 10% (n = 4 [fSCIG 10%-relapse group]; n = 16 [placebo-relapse group]). Responder rate (95% confidence interval) was 100.0% (80.6%-100.0%) in the placebo-relapse group and 95.0% (76.4%-99.1%) in the overall-relapse population. Across all patients, median time to functional improvement was 25 days. At treatment cessation, mean changes from pre-IVIG 10% baseline in adjusted INCAT and R-ODS centile scores were -1.9 and 12.9, respectively.ConclusionsIVIG 10% effectively treated CIDP relapse and improved functional abilities.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWiley-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/ene.70110-
dc.relation.ispartofEuropean Journal of Neurology, 2025, vol. 32, num. 4, p. e70110-
dc.relation.urihttps://doi.org/10.1111/ene.70110-
dc.rightscc by-nc (c) Pasnoor, Mamatha et al., 2025-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalalties autoimmunitàries-
dc.subject.classificationImmunoglobulina G-
dc.subject.classificationImmunoglobulines-
dc.subject.classificationMalalties del sistema nerviós-
dc.subject.otherAutoimmune diseases-
dc.subject.otherImmunoglobulin G-
dc.subject.otherImmunoglobulins-
dc.subject.otherNervous system Diseases-
dc.titleThe Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2025-06-19T14:41:00Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid40247653-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))



This item is licensed under a Creative Commons License Creative Commons